¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"clinical material"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • clinical medicine
    ÀÓ»óÀÇÇÐ
  • clinical otosclerosis
    ¹ßÇö±Í°æÈ­Áõ
  • clinical pathology
    ÀÓ»óº´¸®ÇÐ
  • clinical record
    ÀÓ»ó±â·Ï
  • clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®, ÀÓ»óÄ¡±Ù
  • clinical sign
    ÀÓ»ó¡ÈÄ
  • clinical significance
    ÀÓ»óÀûÁ߿伺
  • clinical skill
    ÀÓ»ó¼ú±â
  • clinical trial
    ÀÓ»ó½ÃÇè
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • good clinical practice
    ÀǾàǰÀÓ»ó½ÃÇè°ü¸®±âÁØ
  • objective structured clinical examination
    °´°ü±¸Á¶È­Áø·á½ÃÇè
  • structured clinical interview
    ±¸Á¶È­ÀÓ»ó¸éÁ¢
  • antifriction material
    ¸¶Âû°¨¼ÒÀç
  • acoustic material
    ¼Ò¸®Èí¼öÀç, ÈíÀ½Àç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • clinical mycology
    ÀÓ»óÁø±ÕÇÐ
  • clinical otosclerosis
    ¹ßÇö±Í°æÈ­Áõ
  • clinical record
    ÀÓ»ó±â·Ï
  • clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®
  • clinical sign
    ÀÓ»ó¡ÈÄ
  • clinical significance
    ÀÓ»óÀûÁ߿伺
  • clinical skill
    ÀÓ»ó¼ú±â
  • clinical specimen
    ÀÓ»ó°Ë»ç¹°
  • clinical syndrome
    ÀÓ»óÁõÈıº
  • clinical trial
    ÀÓ»ó½ÃÇè
  • clinical ward
    ÀÓ»óº´µ¿
  • clinical dementia rating scale
    ÀÓ»óÄ¡¸ÅÆò°¡Ã´µµ
  • clinical target volume
    ÀÓ»óÇ¥ÀûüÀû
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • good clinical practice
    ÀǾàǰÀÓ»ó½ÃÇè°ü¸®±âÁØ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • impression material
    ÀλóÀç(ìÔßÚî§).
  • infectious material handling
    °¨¿°¼º¹°ÁúÃë±Þ
  • prosthetic material
    Àΰøº¸ÀåÀç·á(ìÑÍïÜÁíûî§è÷).
  • radioactive material
    ¹æ»ç¼º¹°Áú
  • radioopaque material
    ¹æ»ç¼± ºñÅõ°ú¼º ¹°Áú
  • radiopaque material
    ¹æ»ç¼± ºñÅõ°ú¼º ¹°Áú
  • raw material
    ¿ø·á(ê«è÷).
  • reference material
    ´ëÁ¶¹°Áú.
  • reference material
    Âü°í¹°Áú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • elastic impression material
    ź¼ºÀλóÀç(¡­ìÔßÚî§).
  • embolic material
    »öÀü ¹°Áú
  • grinding material
    ¿¬¸¶Àç(æÚبî§).
  • hazardous material handling
    À§Çè¹°ÁúÃë±Þ
  • hydrocolloidal impression material
    ¼ö¼ºÄÝ·ÎÀ̵åÀλóÀç(¡­ìÔßÚî§).
  • hygroscopic material
    Èí¼ö¼º ¹°Áú
  • impression material
    ÀλóÀç(ìÔßÚî§).
  • infectious material handling
    °¨¿°¼º¹°ÁúÃë±Þ
  • investing material
    ¸Å¸ôÁ¦(ØØÙÒð¥), ÇǺ¹.
  • natural abrasive material
    õ¿¬¿¬»èÀç·á(ô¸æÔæÚÞûî§è÷).
  • orthodontic material
    ±³Á¤¿ë Àç·á.
  • prosthetic material
    Àΰøº¸ÀåÀç·á(ìÑÍïÜÁíûî§è÷).
  • radioactive material
    ¹æ»ç¼º¹°Áú
  • radioopaque material
    ¹æ»ç¼± ºñÅõ°ú¼º ¹°Áú
  • radiopaque material
    ¹æ»ç¼± ºñÅõ°ú¼º ¹°Áú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CM California mastitis [test]; calmodulin; capreomycin; carboxymethyl; cardiac murmur; cardiac muscle; ...
CPS carbamoylphosphate synthetase; cardioplegic perfusion solution; centipoise; cervical pain syndrome; ...
DCP dicalcium phosphate; Diploma in Clinical Pathology; Diploma in Clinical Psychology; District Communi...
ALM aerial lentiginous melanoma; alveolar living material
A-MAT amorphous material
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MELM Met-enkephalin-like material
NSM Neurosecretory material
RM reference material
SRM Standard Reference Material
SAM Surface-associated material
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • clinical unit
    ÀÓ»ó ´ÜÀ§
  • clinical-pathological correlation
    ÀÓ»ó-º´¸®ÇÐÀû »óÈ£°ü°è
  • controlled clinical study
    °ü¸®È­ ½ÃÇè, °ü¸®È­ ÀÓ»ó ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ÀÓ»ó ½ÃÇè
  • early clinical symptom
    Ãʱâ ÀÓ»ó Áõ»ó
  • lengthening of the clinical crown
    ÀÓ»ó Ä¡°ü ¿¬Àå¼ú
  • active material
    Ȱ¼º ¹°Áú
    È­ÇÐ ¹ÝÀÀ¿¡ À־ Ã˸ÅÀÇ ¹ÝÀÀ ÃËÁø ´É·ÂÀ» Ȱ¼ºÈ­ ½ÃŰ´Â ¹°Áú.
  • agar impression material
    ¾Æ°¡ ÀλóÀç
    ¿ì¹µ°¡»ç¸®¿¡¼­ ÃßÃâÇÑ ÇÑõÀ» »ç¿ëÇÑ ÀλóÀç·Î¼­, °¡¿­³Ã°¢À¸·Î Á¹-°Ö º¯È­¸¦ ¹Ýº¹ÇÏ´Â °¡¿ª¼º ÇÏÀ̵å·ÎÄÝ·ÎÀ̵å ÀλóÀçÀÌ´Ù. ź¼ºÀÌ Å©±â ¶§¹®¿¡ ¾ð´õÄÆ ºÎÀ§ÀÇ Àλó 䵿¿¡ Àû´çÇÏ´Ù.
  • antifriction material
    Ç׸¶Âû ¹°Áú
  • base material
    ±âÃÊ ¹°Áú, »ó Àç·á
  • cast material
    ÁÖÁ¶¿ë Àç·á
  • ceramic material
    µµÀç
  • colouring material
    Âø»öÁ¦
  • contrast material
    Á¶¿µ ¹°Áú, Á¶¿µÁ¦
  • dental material
    Ä¡°ú Àç·á
    Ä¡°ú ÀÇ·á ½Ã¼ú¿¡ »ç¿ëµÇ´Â ¸ðµç Àç·á.
  • die material
    ¸ðÇü Àç·á
    Ä¡ÇüÀ» Á¦ÀÛÇϱâ À§ÇÑ Àç·á·Î¼­ °æ¼®°í, Àú¿ëÀ¶ ±Ý¼Ó, ¾Æ¸»°¨ µîÀÌ ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
impression material Any substance or combination of substances used for making a negative reproduction or impression.
(05 Mar 2000)
iodinated contrast material A substance that contains iodine that can be injected, swallowed or given as an enema for the purpose of diagnostics. Iodinated contrast is radiopaque. This means that conventional X-rays will highlight the course of the contrast in the body.
(27 Sep 1997)
type material <zoology> A collective term for all type specimens. Zoologists should ensure that such material is transferred as quickly as possible to public institutions where their safety is guaranteed and they are accessible to other workers.
(09 Jan 1998)
unconsolidated parent material <ecology> Material from which a soil develops.
(09 Oct 1997)
fertile material <physics> In nuclear physics, this refers to a nuclide which converts to fissile material upon neutron capture and subsequent radioactive decay.
Examples include Uranium-238 and Thorium-232.
(09 Oct 1997)
fill material Any material used for the primary purpose of replacing an aquatic area with dry land or of changing the bottom elevation of a waterbody. The term does not include any pollutant discharged into the water primarily to dispose of waste.
(09 Oct 1997)
fissile material <radiobiology> Material containing a large number of easily fissionable nuclei which give off multiple neutrons in the fission process. Usual meaning is that if a sufficiently large amount of fissile material is put together, a fission chain reaction can occur. Sometimes used synonymously with fissionable material, i.e., material that can be fissioned (though often under restricted circumstances, such as only with thermal (slow) neutrons). A more restricted meaning use of fissile material limits the concept to those materials which can be fissioned by neutrons of all energies (fast & slow).
Examples include Uranium-235 and Plutonium-239.
(09 Oct 1997)
Addison's clinical planes A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison.
(05 Mar 2000)
pathology, clinical A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids.
(12 Dec 1998)
chemistry, clinical The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy.
(12 Dec 1998)
pharmacology, clinical The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.
(12 Dec 1998)
phase I clinical trial <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose.
They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies.
The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs.
(31 Dec 1997)
phase II clinical trial <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study.
(31 Dec 1997)
phase III clinical trial <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments.
Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials.
(31 Dec 1997)
Millon clinical multiaxial inventory A paper and pencil test, consisting of 20 clinical scales derived from 175 self-descriptive statements, and developed in 1977 for use in the assessment of psychopathology and the more enduring patterns of personality; specifically designed to correspond with some of the disorders of personality included in the Diagnostic and Statistical Manual of Mental Disorders used in diagnosis by mental health professionals.
Synonym: Millon clinical multiaxial inventory.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • source material
    ¿¬±¸ ÀÚ·á
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á